



Our STN: BL 125752/258

**SUPPLEMENT APPROVAL**

January 27, 2025

ModernaTX, Inc.

Attention: (b) (6)

325 Binney Street

Cambridge, MA 02142

Dear (b) (6)

We have approved your request received on September 27, 2024, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for mRNA-1273 COVID-19 Vaccine (SPIKEVAX), manufactured at Rovi Pharma Industrial Services, S.A. Alcala de Henares (Madrid, Spain) to include the following:

- two new package configurations (a carton containing 2 individual single-dose pre-filled syringes and a blister pack of 2 single-dose pre-filled syringes),
- data supporting thaw times for the two new package configurations and a revised thaw time for cartons of 10 pre-filled syringes, and
- updates to the SPIKEVAX package insert with information regarding the new packaging and thaw times.

## **LABELING**

We hereby approve the draft content of labeling: Package Insert submitted under amendment 2, dated January 8, 2025, and the draft carton labels submitted on September 27, 2024.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>.

Content of labeling must be identical to the Package Insert submitted on January 8, 2025. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

## **CARTON AND CONTAINER LABELS**

Please electronically submit final printed carton labels identical to the carton labels submitted on September 27, 2024, according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications* at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-certain-human-pharmaceutical-product-applications>.

All final labeling should be submitted as Product Correspondence to this BLA, STN BL 125752 at the time of use and include implementation information on Form FDA 356h.

## **ADVERTISING AND PROMOTIONAL LABELING**

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the (b) (6) at the following address:

Food and Drug Administration  
Center for Biologics Evaluation and Research  
Document Control Center  
10903 New Hampshire Ave.  
WO71–G112  
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

For each pending supplemental application for this BLA that includes proposed revised labeling, please submit an amendment to update the proposed revised labeling with the changes approved today.

We will include the information contained in the above-referenced supplement in your BLA file.

Sincerely,

(b) (6)

Office of Vaccines Research and Review  
Center for Biologics Evaluation and Research